Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ABBV-47D11 and ABBV-2B04 as Monotherapy or Combination Therapy in Adults With COVID-19
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2021
Price :
$35
*
At a glance
- Drugs ABBV 47D11 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors AbbVie
- 30 Aug 2021 Status changed from active, no longer recruiting to completed.
- 18 May 2021 Planned End Date changed from 5 Sep 2021 to 28 Aug 2021.
- 18 May 2021 Planned primary completion date changed from 5 Sep 2021 to 28 Aug 2021.